http://www.diamyd.com/ Diamyd Medical Press Releses. Copyright 2010. All rights reserved. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=504986 Per den 30 juli 2010 uppgår aktiekapitalet i Diamyd Medical AB (publ.) till 14 530 138,50 kronor. Det totala antalet röster uppgår till 4 200 116 och det totala antalet aktier till 29 060 277, varav 1 437 876 aktier av serie A med en (1) röst vardera och 27 622 401 aktier av serie B med en tiondels (1/10) röst vardera. Anledningen till förändringen är utnyttjandet av tilldelade personaloptioner i ... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=504986 Fri, 30 Jul 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=504987 As of July 30, 2010, the share capital in Diamyd Medical AB (publ.) is 14,530,138.50 SEK. The total number of votes is 4,200,116 and the total number of shares is 29,060,277, divided among 1,437,876 shares of series A (1 vote) and 27,622,401 shares of series B (1/10 vote). This change is due to the exercise of granted employee stock options in the stock option plans of 2007/2010, approved by the... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=504987 Fri, 30 Jul 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=504878 Diamyd Medical AB har erhållit upfront-betalningen om 45 miljoner dollar av Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), ett företag inom Johnson & Johnson. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=504878 Thu, 29 Jul 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=504879 Diamyd Medical AB has received the upfront payment of USD 45 million from Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=504879 Thu, 29 Jul 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=503737 Diamyd Medical AB:s avtal med Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), ett företag inom Johnson & Johnson, har trätt i kraft i och med att amerikanska konkurrensmyndigheten godkänt det. Avtalet meddelades 22 juni, 2010. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=503737 Fri, 16 Jul 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=503738 Diamyd Medical AB has received antitrust clearance that closes the transaction announced on June 22, 2010 with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=503738 Fri, 16 Jul 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=501106 I vd-ordet i dagens delårsrapport konstaterar Diamyd Medicals vd och koncernchef Elisabeth Lindner att ett nytt kapitel i bolagets historia startat i och med förra veckans avtal med Ortho-McNeil-Janssen Pharmaceuticals, Inc. för utveckling och kommersialisering av diabetesvaccinet Diamyd®. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=501106 Thu, 01 Jul 2010 08:35:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=501107 In her comments in today's quarterly report, Elisabeth Lindner, President and CEO of Diamyd Medical, notes that a new chapter has begun in the Company's history with last week's agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to develop and commercialize the Diamyd® diabetes therapy. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=501107 Thu, 01 Jul 2010 08:35:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=501097 Delårsrapport Stockholm 1 juli 2010  1 september 2009 - 31 maj 2010 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=501097 Thu, 01 Jul 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=501098 Third quarter report for Diamyd Medical AB (publ.), fiscal year 2009/2010 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=501098 Thu, 01 Jul 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=500859 Per den 30 juni 2010 uppgår aktiekapitalet i Diamyd Medical AB (publ.) till 14 507 585 kronor. Det totala antalet röster uppgår till 4 195 605 och det totala antalet aktier till 29 015 170, varav 1 437 876 aktier av serie A med en (1) röst vardera och 27 577 294 aktier av serie B med en tiondels (1/10) röst vardera. Anledningen till förändringen är utnyttjandet av tilldelade personaloptioner i... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=500859 Wed, 30 Jun 2010 11:44:03 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=500860 As of June 30, 2010, the share capital in Diamyd Medical AB (publ.) is 14,507,585 SEK. The total number of votes is 4,195,605 and the total number of shares is 29,015,170, divided among 1,437,876 shares of series A (1 vote) and 27,577,294 shares of series B (1/10 vote). This change is due to the exercise of granted employee stock options in the stock option plans of 2007/2010, approved by the... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=500860 Wed, 30 Jun 2010 11:44:03 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=498941 Diamyd Medical AB har tecknat avtal med Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), ett företag inom Johnson & Johnson, om att utveckla och kommersialisera diabetesvaccinet Diamyd®. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=498941 Tue, 22 Jun 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=498942 Diamyd Medical AB has signed an agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company, to develop and commercialize the Diamyd® diabetes therapy. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=498942 Tue, 22 Jun 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=487560 Per den 30 april 2010 uppgår aktiekapitalet i Diamyd Medical AB (publ.) till 14 500 052,5 kronor. Det totala antalet röster uppgår till 4 194 099 och det totala antalet aktier till 29 000 105, varav 1 437 876 aktier av serie A med en (1) röst vardera och 27 562 229 aktier av serie B med en tiondels (1/10) röst vardera. Anledningen till förändringen är genomförandet av en riktad emission av... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=487560 Fri, 30 Apr 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=487561 As of April 30, 2010, the share capital in Diamyd Medical AB (publ.) is 14,500,052.5 SEK. The total number of votes is 4,194,099 and the total number of shares is 29,000,105, divided among 1,437,876 shares of series A (1 vote) and 27,562,229 shares of series B (1/10 vote). The change is due to a direct placement of new shares. The Board of Diamyd decided on the new issue based on the... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=487561 Fri, 30 Apr 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=486761 I vd-ordet i dagens delårsrapport beskriver Diamyd Medicals vd och koncernchef Elisabeth Lindner framstegen i de avgörande fas III-studierna med bolagets ledande läkemedelskandidat, Diamyd®, och kommenterar bolagets strategier och satsningar för att bygga ett specialiserat nordiskt läkemedelsbolag. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=486761 Wed, 28 Apr 2010 08:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=486762 In her comments in today's quarterly report, Elisabeth Lindner, President and CEO of Diamyd Medical, describes the progress in the decisive Phase III studies with the Company's lead drug candidate Diamyd®, and comments on the Company's strategies and efforts to build a Nordic specialty pharmaceutical company. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=486762 Wed, 28 Apr 2010 08:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=486758 Delårsrapport Stockholm 28 april 2010 1 september 2009 - 28 februari 2010 Delårsrapport 2 Diamyd Medical AB (publ.), Räkenskapsåret 2009/2010 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) Andra kvartalet 1 december 2009 - 28 februari 2010 -Koncernens nettoomsättning under andra kvartalet uppgick till 0,2 (0,8) MSEK -Resultat efter finansnetto för andra kvartalet uppgick till... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=486758 Wed, 28 Apr 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=486759 Quarterly report, Stockholm, April 28, 2010 September 1, 2009 - February 28, 2010 Second quarter report for Diamyd Medical AB (publ), fiscal year 2009/2010 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY Second quarter December 1, 2009 - February 28, 2010 -Group net sales for the second quarter was MSEK 0.2 (0.8) -Loss before tax for the second quarter was MSEK -26.6 (-15.4)... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=486759 Wed, 28 Apr 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=481329 Diamyd Medical has accepted an offer from an investment fund managed from New York by a Swedish-American team to issue 291,667 new B shares in a direct placement at 120 SEK per share. The issue price corresponds to the average market price of the past 30 trading days. Total proceeds for Diamyd amounts to 35 MSEK. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=481329 Wed, 31 Mar 2010 14:26:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=481327 Diamyd Medical har accepterat ett erbjudande från en fond som förvaltas av ett svensk-amerikanskt team i New York att emittera 291 667 nya B-aktier till priset 120 SEK per aktie i en riktad emission. Emissionskursen motsvarar de 30 senaste handelsdagarnas genomsnittliga marknadspris. Totalt tillförs Diamyd 35 MSEK. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=481327 Wed, 31 Mar 2010 14:25:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=481111 Per den 31 mars 2010 uppgår aktiekapitalet i Diamyd Medical AB (publ.) till 14 354 219 kronor. Det totala antalet röster uppgår till 4 164 932 och det totala antalet aktier till 28 708 438, varav 1 437 876 aktier av serie A med en (1) röst vardera och 27 270 562 aktier av serie B med en tiondels (1/10) röst vardera. Anledningen till förändringen är utnyttjandet av tilldelade personaloptioner i... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=481111 Wed, 31 Mar 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=481112 As of March 31, 2010, the share capital in Diamyd Medical AB (publ.) is 14,354,219 SEK. The total number of votes is 4,164,932 and the total number of shares is 28,708,438, divided among 1,437,876 shares of series A (1 vote) and 27,270,562 shares of series B (1/10 vote). This change is due to the exercise of granted employee stock options in the stock option plans of 2007/2010, approved by the... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=481112 Wed, 31 Mar 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=479460 The FDA has granted Orphan Drug Designation of Diamyd Medical´s lead drug candidate Diamyd®. Orphan drugs qualify for seven years of market exclusivity from the date of US marketing approval, tax credits for clinical research and a waiver for FDA user fees. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=479460 Tue, 23 Mar 2010 18:55:48 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=479459 Den amerikanska läkemedelsmyndigheten FDA har beviljat Diamyd Medicals ledande läkemedelskandidat, Diamyd®, särläkemedelsstatus (Orphan Drug Designation). Särläkemedel åtnjuter sju års marknads-exklusivitet i USA, skattelättnader för klinisk forskning och befrielse från vissa FDA-avgifter. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=479459 Tue, 23 Mar 2010 18:52:19 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=476725 Diamyd Medical meddelar idag att 100 patienter har inkluderats i bolagets pågående amerikanska fas III-studie DiaPrevent. Det globala fas III-programmet med bolagets ledande läkemedelskandidat Diamyd® har därmed rekryterat mer än 430 barn med nydiagnostiserad typ 1-diabetes i Europa och USA. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=476725 Wed, 10 Mar 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=476726 Diamyd Medical announces today that one hundred study participants have been included in the ongoing US Phase III study, DiaPrevent. The global Phase III program with the company's lead drug candidate Diamyd® has thereby enrolled more than 430 children newly diagnosed with type 1 diabetes in Europe and the USA. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=476726 Wed, 10 Mar 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=475712 Med anledning av ökad omsättning i aktien kommer Mangold Fondkommission AB inte längre att agera som likviditetsgarant i Diamyd Medicals B-aktie. Nuvarande avtal om likviditetsgaranti upphör att gälla 2010-03-05. Någon ny likviditetsgarant har inte utsetts. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=475712 Thu, 04 Mar 2010 08:20:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=475713 Due to increased turnover in the share Mangold Fondkommission AB will no longer act as liquidity provider in Diamyd Medical's B-share. The current liquidity provider agreement will expire on March 5, 2010. A new liquidity provider has not been appointed. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=475713 Thu, 04 Mar 2010 08:20:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469407 As of January 29, 2010, the share capital in Diamyd Medical AB (publ.) is 14 330 494 SEK. The total number of votes is 4 160 187 and the total number of shares is 28 660 988, divided among 1 437 876 shares of series A (1 vote) and 27 223 112 shares of series B (1/10 vote). This change is due to the exercise of granted employee stock options in the stock option plan 2007/2010, approved by the... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469407 Fri, 29 Jan 2010 09:01:34 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469405 Per den 29 januari 2010 uppgår aktiekapitalet i Diamyd Medical AB (publ.) till 14 330 494 kronor. Det totala antalet röster uppgår till 4 160 187 och det totala antalet aktier till 28 660 988, varav 1 437 876 aktier av serie A med en (1) röst vardera och 27 223 112 aktier av serie B med en tiondels (1/10) röst vardera. Anledningen till förändringen är teckning av tilldelade personaloptioner i... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469405 Fri, 29 Jan 2010 09:00:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469400 In her comments in today's quarterly report Elisabeth Lindner, President and CEO of Diamyd Medical, says that the Company's objective is to file the Diamyd® diabetes vaccine for market approval in 2011 - a goal that isn't very far off now. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469400 Fri, 29 Jan 2010 08:55:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469398 Diamyd Medicals vd och koncernchef Elisabeth Lindner kommenterar i vd-ordet i dagens delårsrapport att bolagets målsättning är att sända in ansökan om marknadsgodkännande för diabetesvaccinet Diamyd® under 2011. Ett mål som nu inte ligger allt för långt fram i tiden. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469398 Fri, 29 Jan 2010 08:54:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469410 Delårsrapport 1 Diamyd Medical AB (publ.), Räkenskapsåret 2009/2010 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469410 Fri, 29 Jan 2010 08:44:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469411 First quarter report for Diamyd Medical AB (publ), fiscal year 2009/2010 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=469411 Fri, 29 Jan 2010 08:44:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467797 Diamyd Medical meddelar att bolaget genomför en uppdelning av aktier (split) som innebär att varje nuvarande aktie delas upp på två aktier av samma aktieslag. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467797 Wed, 20 Jan 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467798 Diamyd Medical announces today that the company executes a 2:1 division of shares (i.e. a split), meaning that each share is divided into two shares of the same class. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467798 Wed, 20 Jan 2010 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467318 IMPORTANT EVENTS DURING THE FISCAL YEAR . Children from the age of 10 years were included and accelerated patient recruitment was initiated in the American Phase III study of the Diamyd® diabetes vaccine. . The first children were vaccinated in a prevention study with Diamyd® intended to prevent type 1 diabetes in Swedish children at high risk of developing the disease. . A study on Diamyd® was... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467318 Tue, 22 Dec 2009 15:39:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467129 Diamyd Medical meddelar idag att den amerikanska läkemedelsmyndigheten, FDA, har godkänt att Diamyd®-vaccinet testas i barn ner till tre års ålder i TrialNets GAD-studie som omfattar 126 patienter som nyligen fått typ 1-diabetes i Nordamerika. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467129 Mon, 14 Dec 2009 08:26:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467307 Diamyd Medical reports today that the United States Food and Drug Administration (FDA) has approved the experimental use of Diamyd® vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset type 1 diabetes patients in North America. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467307 Mon, 14 Dec 2009 08:26:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467126 Vid Diamyd Medicals ordinarie bolagsstämma den 11 december meddelar VD Elisabeth Lindner att bolaget står starkare än någonsin förut. Den första av bolagets fas III-studier med diabetesvaccinet Diamyd® är fullrekryterad och rekryteringstakten i den andra fas III-studien ökar stadigt. Därutöver har flera barn vaccinerats i en svensk preventionsstudie i syfte att förhindra typ 1-diabetes. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467126 Fri, 11 Dec 2009 17:03:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467306 At Diamyd Medical's ordinary Annual General Meeting on December 11, CEO Elisabeth Lindner announced that Diamyd stands stronger than ever before. The first of the company's Phase III studies of the Diamyd® diabetes vaccine is fully recruited and the recruitment of the other Phase III study is steadily increasing. Additionally, several children have been vaccinated in a Swedish prevention study of... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467306 Fri, 11 Dec 2009 17:03:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467122 Diamyds partnerskapsförhandlingar, som bolaget tidigare har informerat om, rörande utlicensiering av marknadsrättigheter för Diamyd®-portföljen är i ett långt framskridet skede. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467122 Wed, 02 Dec 2009 11:04:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467120 Per den 30 november 2009 uppgår aktiekapitalet i Diamyd Medical AB (publ) till 14 313 563 kronor. Det totala antalet röster uppgår till 2 078 400,5 och det totala antalet aktier till 14 313 563, varav 718 938 aktier av serie A med en (1) röst vardera och 13 594 625 aktier av serie B med en tiondels (1/10) röst vardera. Anledningen till förändringen är genomförandet av den företrädesemission av... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467120 Mon, 30 Nov 2009 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467305 As of November 30, 2009, the share capital in Diamyd Medical AB (publ) is 14 313 563 SEK. The total number of votes is 2 078 400,5 and the total number of shares is 14 313 563, divided among 718 938 shares of series A (1 vote) and 13 594 625 shares of series B (1/10 vote). This change is due to the rights issue resolved by the Board of Directors on September 15, 2009, which the extra... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467305 Mon, 30 Nov 2009 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467119 Viktiga händelser under verksamhetsåret - Inkludering av barn från tio års ålder och accelererad patientrekrytering påbörjades i amerikansk fas III-studie med diabetesvaccinet Diamyd®. - Första barnen vaccinerades i preventionsstudie med Diamyd® i syfte att förhindra typ 1-diabetes hos svenska barn med hög risk att få sjukdomen. - Diamyd®-studie publicerades i Europas ledande vetenskapliga... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467119 Fri, 27 Nov 2009 08:35:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467111 Diamyd Medicals årsredovisning för 2008/2009 finns från och med idag tillgänglig på bolagets hemsida, www.diamyd.com. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467111 Fri, 27 Nov 2009 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467304 Diamyd Medical's Annual Report for 2008/2009 is from today available in Swedish on the company website, www.diamyd.com. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467304 Fri, 27 Nov 2009 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467102 Aktieägarna i Diamyd Medical AB (publ) är kallade till årsstämma fredagen den 11 december 2009 kl. 15.00 på IVA Konferenscenter, Grev Turegatan 16 (Wallenbergssalen) i Stockholm. Under punkten 11 på dagordningen, föreslår Diamyds valberedning nu att ytterligare en ledamot väljs in i styrelsen. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467102 Thu, 26 Nov 2009 08:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467302 The shareholders of Diamyd Medical AB (publ) are summoned to the Annual General Meeting on Friday December 11, 2009 at 3:00 p.m. at the IVA Conference Center, Grev Turegatan 16 (Wallenberg auditorium) in Stockholm. Under item 11 in the agenda, Diamyd's Nomination Committee now proposes that an additional Director is elected to the Board of Directors. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467302 Thu, 26 Nov 2009 08:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467100 Diamyd Medical meddelar idag att bolagets europeiska fas III-studie med diabetesvaccinet Diamyd® nu är fullrekryterad. Resultat från studien beräknas kunna presenteras under våren 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467100 Thu, 12 Nov 2009 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467301 Diamyd Medical announces today that the company's European Phase III study of the diabetes vaccine Diamyd® is now fully recruited. It is estimated that results from the study can be reported during spring 2011. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467301 Thu, 12 Nov 2009 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467099 Aktieägarna i Diamyd Medical AB (publ) kallas härmed till årsstämma fredagen den 11 december 2009 kl. 15.00 på IVA Konferenscenter, Grev Turegatan 16 (Wallenbergssalen) i Stockholm. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467099 Wed, 11 Nov 2009 08:39:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467300 The shareholders of Diamyd Medical AB (publ) are hereby summoned to the Annual General Meeting on Friday December 11, 2009 at 3:00 p.m. at the IVA Conference Center, Grev Turegatan 16 (Wallenberg auditorium) in Stockholm. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467300 Wed, 11 Nov 2009 08:39:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467096 Diamyd Inc, Pittsburg, USA, ett helägt dotterbolag till Diamyd Medical, meddelar idag att United States Department of Veterans Affairs (VA) har anslagit 1,84 miljoner dollar till stöd för utveckling av Diamyds Nerve Targeting Drug Delivery System (NTDDS) för nervsmärta vid diabetes. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467096 Tue, 10 Nov 2009 08:28:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467298 Diamyd Inc, Pittsburgh, PA, USA, a wholly-owned subsidiary of Diamyd Medical, Stockholm Sweden, announces today that the United States Department of Veterans Affairs (VA) has awarded a $1.84 million grant to support the development of Diamyd's Nerve Targeting Drug Delivery System (NTDDS) for Diabetic Neuropathic Pain. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467298 Tue, 10 Nov 2009 08:28:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467085 Diamyd Medical meddelar idag att bolagets företrädesemission om knappt 220 MSEK blivit kraftigt övertecknad. Totalt har teckningsanmälningar motsvarande drygt 384 MSEK inkommit. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467085 Thu, 05 Nov 2009 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467297 Diamyd Medical reports today that the Company's rights issue of just under 220 MSEK has been substantially oversubscribed. Subscriptions equal to a total sum of 384 MSEK have been received. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467297 Thu, 05 Nov 2009 08:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467084 Diamyd Medicals vd och koncernchef Elisabeth Lindner meddelar i vd-ordet i dagens bokslutskommuniké, att Diamyd under det senaste året kommit allt närmare förverkligandet av bolagets vision - att i framtiden kunna förebygga och bota den autoimmuna formen av diabetes. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467084 Fri, 23 Oct 2009 08:37:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467295 In her comments in today's year-end report, Elisabeth Lindner, President and CEO of Diamyd Medical, reports that in the last year Diamyd has come ever closer to realizing its vision of being able to prevent and cure the autoimmune form of diabetes in the future. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467295 Fri, 23 Oct 2009 08:37:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467083 Kvartalsrapport 4 Stockholm 23 oktober 2009 Kvartalsrapport 4 Diamyd Medical AB (publ.), Räkenskapsåret 2008/2009 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467083 Fri, 23 Oct 2009 08:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467310 Fourth Quarter Report, Stockholm, October 23, 2009 Fourth Quarter Report for Diamyd Medical AB (publ.), Fiscal Year 2008/2009 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) Fourth quarter, June 1, 2009 - August 31, 2009 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467310 Fri, 23 Oct 2009 08:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467082 Diamyd meddelar idag att bolaget har tecknat ett förlikningsavtal med Apoteket AB rörande en klinisk studie i LADA-patienter, som ogiltigförklarades under 2007. Orsaken till ogiltigförklarandet var motsägande data som gav skäl till misstanke om sammanblandning av läkemedel och placebo. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467082 Wed, 14 Oct 2009 12:11:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467293 Diamyd Medical announces today that the company has executed a settlement agreement with Apoteket AB regarding a clinical study in LADA patients, which was invalidated in 2007. The cause of the invalidation was contradictory data, which gave reason to suspect a mix-up of active drug and placebo. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467293 Wed, 14 Oct 2009 12:11:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467081 Styrelsen i Diamyd Medical AB (publ.) har upprättat prospekt avseende föreliggande nyemission om knappt 220 MSEK med företrädesrätt för befintliga aktieägare. Prospektet finns tillgängligt på svenska på Diamyd Medicals hemsida www.diamyd.com. Villkor för nyemissionen i sammandrag: - Nyemissionen omfattar högst 3.131.091 aktier, varav högst 157.267 A-aktier och högst 2.973.824 B-aktier -... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467081 Wed, 14 Oct 2009 10:40:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467292 The Board of Directors of Diamyd Medical AB (publ) has prepared a prospectus relating to the new issue of just under 220 MSEK with preferential rights for existing shareholders. The prospectus is available in Swedish on Diamyd Medical's website www.diamyd.com. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467292 Wed, 14 Oct 2009 10:40:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467080 Vid dagens extra bolagsstämma i Diamyd Medical AB (publ) beslutades i enlighet med styrelsens förslag att genomföra en nyemission om knappt 220 MSEK med företrädesrätt för befintliga aktieägare. Emissionen är till fullo garanterad av teckningsförbindelser och emissionsgarantier. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467080 Wed, 07 Oct 2009 17:34:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467291 The extra shareholders' meeting at Diamyd Medical AB (publ) held today decided, in accordance with the proposal put forward by the Board of Directors, to implement a new share issue of just under 220 MSEK with preferential rights for existing shareholders. The rights issue is 100% underwritten through subscription undertakings and underwriting guarantees. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467291 Wed, 07 Oct 2009 17:34:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467079 Diamyd Medical meddelar idag att 90 procent av de totalt 320 barn och ungdomar med typ 1-diabetes, som ingår i bolagets europeiska fas III-studie med diabetesvaccinet Diamyd®, nu har inkluderats och fått injektioner med Diamyd® eller placebo. Bolaget bedömer att samtliga deltagare kommer att ha inkluderats i studien under november månad 2009. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467079 Wed, 07 Oct 2009 08:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467289 Diamyd Medical announces today that 90 percent of the total 320 children and adolescents with type 1 diabetes due to participate in the company's European Phase III study with the diabetes vaccine Diamyd® have now been included and have received injections of Diamyd® or placebo. The company expects all participants to have been included in the study by November 2009. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467289 Wed, 07 Oct 2009 08:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467078 Diamyd Medical meddelar idag att bolaget har slutit ett avtal med Inclinix Inc., North Carolina i USA, för accelererad rekrytering av barn och ungdomar som nyligen har fått typ 1-diabetes till den amerikanska fas III-studien med diabetesvaccinet Diamyd®. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467078 Thu, 01 Oct 2009 08:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467288 Diamyd Medical announces today that the company has signed an agreement with Inclinix Inc., North Carolina, for accelerated recruitment of children and adolescents recently diagnosed with type 1 diabetes in the US Phase III study of the diabetes vaccine Diamyd®. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467288 Thu, 01 Oct 2009 08:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467077 Diamyd Medicals huvudägare Bertil Lindkvist och Anders Essen-Möller utökar sina teckningsförbindelser och avser att fullt ut nyttja sina teckningsrätter. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467077 Wed, 16 Sep 2009 13:06:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467287 The Diamyd Medical Board of Directors has, subject to approval at the shareholder's meeting, decided to implement a preferential rights issue of 220 MSEK. The new share issue strengthens Diamyd´s negotiation position in the ongoing process to find an industrial partner as well as secures financing of the Phase III studies. The rights issue is 100% underwritten through undertakings by existing... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467287 Tue, 15 Sep 2009 12:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467076 Diamyd Medicals styrelse har, villkorat av bolagsstämmas godkännande, beslutat att genomföra en företrädesemission om 220 Mkr. Nyemissionen stärker Diamyds förhandlingsposition i den pågående processen att hitta en industriell partner samtidigt som finansieringen för fas III-studierna tryggas. Emissionen är till 100 procent garanterad genom teckningsförbindelser och garantier. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467076 Tue, 15 Sep 2009 08:35:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467075 Diamyd Medical meddelar idag att bolagets 4-årsuppföljning av typ 1-diabetespatienter som ingick i bolagets fas II-studie visar en tydlig positiv trend. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467075 Thu, 03 Sep 2009 09:07:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467286 Diamyd Medical announced today that the company's 4-year follow-up of type 1 diabetes patients included in the company's Phase II study shows a clear positive trend. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467286 Thu, 03 Sep 2009 09:07:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467074 Diamyd Medical meddelar idag att från och med den första september kommer barn från 10 års ålder med typ 1-diabetes att inkluderas i bolagets amerikanska fas III-studie med diabetesvaccinet Diamyd®. Bolaget tredubblar dessutom antalet kliniker och satsar på utökade rekryteringsaktiviteter i USA. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467074 Thu, 27 Aug 2009 08:52:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467285 Diamyd Medical reported today that from September 1, children from 10 years of age with type 1 diabetes will be included in the company's US Phase III study of the Diamyd® diabetes vaccine. The company is also trebling the number of clinics and is investing in expanded recruitment activities in the US. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467285 Thu, 27 Aug 2009 08:52:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467281 Diamyd Medical's President and CEO comments in the company's interim report today on several significant advances during the period, including the positive development of the company's Phase III program. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467281 Wed, 01 Jul 2009 10:33:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467311 Quarterly report, Stockholm, July 1, 2009 Third quarter report for Diamyd Medical AB (publ), fiscal year 2008/2009 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) March 1, 2009 - May 31, 2009 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467311 Wed, 01 Jul 2009 10:29:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467072 Diamyd Medicals vd och koncernchef kommenterar i bolagets delårsrapport idag flera betydelsefulla framsteg under perioden, däribland den positiva utvecklingen av bolagets fas III-program. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467072 Wed, 01 Jul 2009 08:34:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467071 Delårsrapport Stockholm 1 juli 2009 Delårsrapport 3 Diamyd Medical AB (publ.), Räkenskapsåret 2008/2009 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) 1 mars 2009 - 31 maj 2009 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467071 Wed, 01 Jul 2009 08:31:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467070 Diamyd Medical meddelar idag att de första barnen har vaccinerats i en unik preventionsstudie med diabetesvaccinet Diamyd®. Syftet med studien är att utvärdera om vaccination med Diamyd®kan förhindra eller fördröja att barn med hög risk för att få typ 1-diabetes får sjukdomen. Det är första gången någonsin vaccination prövas i förebyggande syfte mot denna kroniska sjukdom. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467070 Mon, 22 Jun 2009 12:02:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467278 with the diabetes vaccine Diamyd®. The purpose of the study is to investigate whether vaccination with Diamyd® may prevent or delay that children, with high risk to develop type 1 diabetes, get the disease. This is the first time ever that vaccination is tested with the purpose to prevent this chronic disease. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467278 Mon, 22 Jun 2009 12:02:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467068 Diamyd Medical meddelar idag att bolaget har fått godkännande från den amerikanska läkemedelsmyndigheten, FDA, att inkludera barn med typ 1-diabetes från 10 års ålder i bolagets fas III-studie med diabetesvaccinet Diamyd®. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467068 Mon, 08 Jun 2009 09:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467277 Diamyd Medical reported today that the company has received approval from the US Food and Drug Administration, FDA, to include children with type 1 diabetes from 10 years of age in the company's Phase III study with the diabetes vaccine Diamyd®. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467277 Mon, 08 Jun 2009 09:30:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467067 Diamyd Medical meddelar idag att 166 av de totalt 320 patienter, som ingår i den europeiska fas III-studien med diabetesvaccinet Diamyd®, nu har inkluderats och behandlats. Diskussion pågår med berörda läkemedelsmyndigheter om hur den goda rekryteringstakten i Europa kan nyttjas optimalt i det globala fas III-programmet. Bolaget bedömer att programmet ska vara fullt rekryterat under 2009. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467067 Thu, 14 May 2009 10:40:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467275 Diamyd Medical reported today that 166 out of a total of 320 patients, who are part of the European Phase III study of the Diamyd® diabetes vaccine, have now been included in the study. Discussions with regulatory agencies are ongoing regarding how the brisk rate of recruitment in Europe can best be utilized in Diamyd's global Phase III program. The company estimates that the program will be fully... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467275 Thu, 14 May 2009 10:40:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467065 Diamyd Medical meddelar att den ansedda vetenskapliga tidskriften Diabetologia har publicerat en artikel med studieresultat, som visar att Diamyd®-vaccinet, fortfarande efter fem år, signifikant minskar risken för att patienter med LADA (Latent Autoimmune Diabetes in Adults) behöver insulinbehandling. Resultaten, som nu publiceras, har tidigare presenterats vid EASD mötet i Rom i augusti 2008. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467065 Mon, 04 May 2009 10:13:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467274 Diamyd Medical reports that the respected scientific journal Diabetologia has published an article containing the results of a study demonstrating that the Diamyd® vaccine significantly reduces the risk that patients with LADA (Latent Autoimmune Diabetes in Adults) will require treatment with insulin still after five years. The results that now have been published, were previously presented at the... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467274 Mon, 04 May 2009 10:13:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467064 Diamyd Medicals vd och koncernchef kommenterar i bolagets halvårsrapport idag det goda nyhetsflöde som bolaget har levererat under kvartalet och som berör fem parallella studier i totalt tio länder. Bolaget har efter periodens slut tillförts ett kapitaltillskott om totalt 28 MSEK, i och med att nya aktier tecknades med stöd av teckningsoptionen DIAM TO 2B. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467064 Wed, 29 Apr 2009 08:44:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467270 Today the President and CEO of Diamyd Medical commented in the company's semi-annual report on the steady flow of good news that the company has reported during the quarter, concerning five simultaneous trials in a total of ten countries. After the reporting period the company received a capital injection of MSEK 28, through subscriptions for new shares upon exercise of subscription warrant DIAM... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467270 Wed, 29 Apr 2009 08:44:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467252 Halvårsrapport Stockholm 29 april, 2009 Kvartalsrapport 2 Diamyd Medical AB (publ.), Räkenskapsåret 2008/2009 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) 1 december, 2008 - 28 februari, 2009 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467252 Wed, 29 Apr 2009 08:38:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467262 Semi-Annual Report Stockholm April 29, 2009 Second quarter report for Diamyd Medical AB (publ), fiscal year 2008/2009 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) September 1, 2008 - February 28, 2009 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467262 Wed, 29 Apr 2009 08:38:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467061 Diamyd Medical meddelar idag att teckningen av nya aktier med stöd av teckningsoptionen DIAM TO 2B förstärker bolagets kassa med 28 miljoner SEK. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467061 Thu, 23 Apr 2009 10:12:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467261 Diamyd Medical reports today that the subscription of new shares upon exercise of the subscription warrant DIAM TO2B brought in SEK 28 million in cash injection. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467261 Thu, 23 Apr 2009 10:12:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467060 Diamyd Medical driver två kliniska fas III-studier med diabetesvaccinet Diamyd® på barn och ungdomar nyligen insjuknade i typ 1-diabetes, en i USA och en i nio länder i Europa. Parallellt för nu bolaget diskussioner med läkemedelsmyndigheterna om möjligheten att slå ihop de två studierna till en global studie. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467060 Thu, 16 Apr 2009 09:57:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467259 Diamyd Medical is conducting two clinical Phase III trials of the Diamyd® diabetes vaccine in children and adolescents with recent onset type 1 diabetes: one in the US and one in nine European countries. In parallel the company is discussing with the regulatory agencies about combining the two trials into one global trial. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467259 Thu, 16 Apr 2009 09:57:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467059 Diamyd Medical meddelar idag att bolagets två huvudägare, Bertil Lindquist och Anders Essen-Möller, konverterar vardera 10 000 teckningsoptioner Diamyd TO 2B till aktier i Diamyd Medical AB. Inlösenpriset är 100 kronor per aktie. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467059 Tue, 07 Apr 2009 09:48:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467250 Diamyd Medical is announcing today that the company's two principal owners, Bertil Lindquist and Anders Essen-Möller, is each converting 10,000 Diamyd TO 2B warrants into shares in Diamyd Medical AB. The exercise price is SEK 100 per share. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467250 Tue, 07 Apr 2009 09:48:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467058 Diamyd Medical meddelar idag att bolaget har förvärvat en exklusiv licens för en ny endomorfin-teknologi som kan användas för behandling av neuropatisk smärta som bland annat uppkommer vid diabetes. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467058 Fri, 27 Mar 2009 09:21:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467248 Diamyd Medical reports today that it has acquired an exclusive license for Endomorphin technology that may be used for the treatment of pain, including neuropathic pain, that occurs in diabetes. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467248 Fri, 27 Mar 2009 09:21:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467057 Diamyd Medicals vd Elisabeth Lindner löser in 5000 teckningsoptioner och ökar därmed sitt innehav i Diamyd Medical till 9100 B-aktier. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467057 Tue, 24 Mar 2009 10:46:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467216 Diamyd Medical's CEO Elisabeth Lindner is exercising 5,000 subscription warrants, increasing her holdings in Diamyd Medical to 9,100 Class B shares. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467216 Tue, 24 Mar 2009 10:46:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467055 Anmälan om teckning av aktier med stöd av teckningsoptioner Diamyd Medical TO 2B skall ske under perioden 16 mars - 17 april 2009. Utnyttjas inte teckningsoptionen inom ovan angiven tid förfaller den utan värde. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467055 Thu, 12 Mar 2009 11:17:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467210 Notification for subscription of shares supported by the warrant Diamyd Medical TO 2B shall take place between March 16 and April 17, 2009. If the warrant is not exercised within the period stated above, it will expire without value. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467210 Thu, 12 Mar 2009 11:17:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467056 Diamyd Medical meddelar idag att Type 1 Diabetes TrialNet, ett kliniskt nätverk som finansieras av National Institutes of Health för att förhindra och behandla nydiagnostiserad typ 1 diabetes, har startat rekryteringen av patienter för en klinisk studie i syfte att testa Diamyd®-vaccinets terapeutiska effekt för nyinsjuknade patienter. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467056 Wed, 11 Mar 2009 10:40:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467214 Diamyd Medical announces today that Type 1 Diabetes TrialNet, a clinical network funded by the National Institutes of Health to prevent and treat newly diagnosed type 1 diabetes, has started recruiting patients for a clinical trial testing the Diamyd®-vaccine's therapeutic benefit in individuals with recent-onset type 1 diabetes. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467214 Wed, 11 Mar 2009 10:40:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467054 Diamyd Medical meddelar idag att svenska Läkemedelsverket godkänt en studie med diabetesvaccinet Diamyd® i barn med hög risk att utveckla typ 1-diabetes. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467054 Wed, 04 Mar 2009 09:48:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467208 Diamyd Medical announces today that the Swedish Medical Products Agency has approved a study with the Diamyd® diabetes vaccine in children with high risk to develop type 1 diabetes. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467208 Wed, 04 Mar 2009 09:48:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467053 Styrelseledamöter och ledande befattningshavare har gjort insiderköp i Diamyd Medical AB's aktie. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467053 Fri, 20 Feb 2009 09:21:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467206 Directors of the Board and senior executive have bought shares in Diamyd Medical. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467206 Fri, 20 Feb 2009 09:21:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467052 Diamyd Medical meddelar idag att den europeiska fas III-studien med diabetesvaccinet Diamyd® nu är godkänd i samtliga nio planerade europeiska länder. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467052 Wed, 18 Feb 2009 09:33:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467203 Diamyd Medical announces today that the European Phase III study with the diabetes vaccine Diamyd® has now been approved in all nine of the planned European countries. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467203 Wed, 18 Feb 2009 09:33:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467051 Diamyd Medical har fått godkänt av svenska Läkemedelsverket att fortsätta följa de barn som ingick i bolagets fas II-studie med Diamyd®-vaccinet, som startade för fyra år sedan. Syftet med uppföljningsstudien är att bekräfta vaccinets långtidseffekt. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467051 Mon, 16 Feb 2009 13:06:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467201 Diamyd Medical has received approval from the Swedish Medical Products Agency to continue to follow the children who participated in the company's Phase II study of the Diamyd® diabetes vaccine, which started four years ago. The aim of the follow-up study is to confirm the vaccine's long-term effect. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467201 Mon, 16 Feb 2009 13:06:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467050 Diamyd Medical meddelar idag att en preventionsstudie med diabetesvaccinet Diamyd® har godkänts av den norska Läkemedelsmyndigheten. Som bolaget meddelade den 9 december 2008, är syftet med studien att undersöka sjukdomsförloppet innan typ 1-diabetes bryter ut och om behandling med diabetesvaccinet Diamyd® stoppar förloppet. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467050 Fri, 13 Feb 2009 09:49:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467198 Diamyd Medical reports today that a prevention study with the Diamyd® diabetes vaccine has been approved by the Norwegian Medicines Agency. As previously communicated on December 9, 2008, the objective of the study is to investigate the disease process before type 1 diabetes onset and if treatment with the Diamyd® diabetes vaccine stops the process. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467198 Fri, 13 Feb 2009 09:49:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467049 Diamyd Medical meddelar idag att bolagets VD och koncernchef, Elisabeth Lindner, har blivit inbjuden att tala på BIO CEO & Investor Conference i New York den 9 februari. Presentationen kommer att äga rum kl 14:45 på Waldorf Astoria. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467049 Fri, 06 Feb 2009 08:00:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467194 Diamyd Medical announces today that Elisabeth Lindner, President and Chief Executive Officer of the company, has been invited to speak at the BIO CEO & Investor Conference in New York on February 9. The presentation will take place at 2.45 pm at the Waldorf Astoria. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467194 Fri, 06 Feb 2009 08:00:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467047 Diamyd Medical meddelar att den amerikanska läkemedelsmyndigheten FDA har godkänt en studie med syftet att bevara och eventuellt återställa insulinproduktionen hos patienter som nyligen insjuknat i typ 1-diabetes. I prövningen kommer diabetesvaccinet Diamyd® att testas tillsammans med läkemedel som anses stimulera tillväxten av nya insulinproducerande betaceller. Målet med kombinationsbehandlingen... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467047 Thu, 05 Feb 2009 13:08:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467187 Diamyd Medical reports that the US Food and Drug Administration (FDA) has approved a study designed to preserve and possibly regenerate insulin production in patients with recent onset type 1 diabetes. The trial will test the diabetes vaccine Diamyd® in combination with drugs that are believed to stimulate new beta cell growth. The aim of the combination therapy is to try to restore lost... http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467187 Thu, 05 Feb 2009 13:08:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467176 In today's quarterly report Diamyd Medical's President and CEO, Elisabeth Lindner, comments on the very active period the company has had during the last part of 2008. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467176 Fri, 30 Jan 2009 17:38:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467169 Quarterly report Stockholm January 30, 2009 First quarter report for Diamyd Medical AB (publ), fiscal year 2008/2009 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) September 1, 2008 - November 30, 2008 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467169 Fri, 30 Jan 2009 17:35:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467045 Diamyd Medicals VD och koncernchef Elisabeth Lindner kommenterar i dagens kvartalsrapport den mycket aktiva tid som bolaget haft under sista delen av år 2008. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467045 Fri, 30 Jan 2009 08:05:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467251 Kvartalsrapport Stockholm 30 januari, 2009 Kvartalsrapport 1 Diamyd Medical AB (publ.), Räkenskapsåret 2008/2009 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) 1 september 2008 - 30 november 2008 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467251 Fri, 30 Jan 2009 08:01:00 +0200 http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467043 Bolaget meddelar att det för ett år sedan upptäcktes ekonomiska oegentligheter i ett av dotterbolagen, härrörande från en period före augusti 2006. Omfattningen var inte väsentlig och har ingen påverkan på bolagets resultat efter räkenskapsåret 2005/2006, men ärendet polisanmäldes trots detta och allmän åklagare väckte åtal per den 12 januari 2009. Den åtalade har lämnat bolaget för två år sedan. http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=467043 Thu, 15 Jan 2009 11:01:00 +0200